EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Efficacy and safety of colistin–doxycycline combination therapy in multi-drug resistance Gram-negative infections: a double-blind randomized controlled trial

Shaghayegh Abaft, Zeynab Yassin, Mahdi Ahmadinia, Azadeh Eshraghi, Behnaz Gholizadeh Niari, Sara Minaeian, Maryam Farasatinasab

Infection · 2026

DOI: 10.1007/s15010-025-02698-3 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Infection, 2026. Verfasst von Shaghayegh Abaft und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Pharmaceutical Science Branch, Islamic Azad University, Tehran, Iran. Hauptthemen laut MEDLINE: Colistin, Anti-Bacterial Agents, Drug Resistance, Multiple, Bacterial, Klebsiella Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & OBJECTIVES: Multidrug-resistant (MDR) Klebsiella pneumoniae poses a critical treatment challenge. Colistin remains a last-resort antibiotic but is limited by nephrotoxicity and resistance. Though clinical data are limited, Doxycycline has demonstrated in vitro synergy with colistin. Colistin-meropenem is frequently used as a comparator regimen, despite mixed evidence on its synergistic activity. This study evaluates the efficacy, microbiological response, and safety of colistin-doxycycline versus colistin-meropenem in MDR Gram-negative infections. METHODS: A double-blind, randomized controlled trial was conducted at a teaching hospital. Adult patients with culture-confirmed MDR Klebsiella pneumoniae infections were randomized to receive colistin-doxycycline or colistin-meropenem. The primary outcome was clinical cure, defined as resolution of infection signs without therapy escalation and in-hospital mortality. Secondary outcomes included microbiological eradication, acute kidney injury (AKI), and treatment-related adverse events. Patients were followed throughout hospitalization and for 14 days post-treatment. RESULTS: A total of 46 patients were enrolled, with 23 patients in each group. Clinical cure rates were significantly higher in the colistin-doxycycline group (87.0% vs. 46.7%, p = 0.012), and mortality was lower (69.6% vs. 86.7%, p = 0.017). Microbiological eradication was also superior (p = 0.016), and nephrotoxicity incidence was numerically lower (19.1% vs. 33.3%, p = 0.092). Faster resolution of inflammation (p < 0.05) and reduced need for mechanical ventilation (60.9% vs. 33.3%, p = 0.028) were observed in the colistin-doxycycline group. CONCLUSIONS: Colistin-doxycycline showed superior efficacy to colistin-meropenem in MDR Klebsiella pneumoniae infections, with higher cure rates, better bacterial eradication, and a favorable safety trend. These results support its potential as a possible alternative option in managing MDR Gram-negative infections, though confirmation in larger multicenter trials is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColistinAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialKlebsiella InfectionsDoxycyclineHumansDouble-Blind MethodMaleFemaleMiddle AgedAgedTreatment OutcomeKlebsiella pneumoniaeDrug Therapy, CombinationAdultGram-Negative Bacterial Infections

Stichwörter der Autor:innen

Antibiotic synergyColistinDoxycyclineGram-negative infectionsMultidrug-resistant bacteria

Substanzen

ColistinAnti-Bacterial AgentsDoxycycline

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Pharmaceutical Science Branch, Islamic Azad University, Tehran, Iran.
  • Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.
  • Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Clinical Pharmacy and Pharmacoeconomics, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran.
  • Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran. sara.minaeian@gmail.com.

Zitieren

APA

Abaft, S., Yassin, Z., Ahmadinia, M., Eshraghi, A., Niari, B. G., Minaeian, S., & Farasatinasab, M. (2026). Efficacy and safety of colistin–doxycycline combination therapy in multi-drug resistance Gram-negative infections: a double-blind randomized controlled trial. Infection. https://doi.org/10.1007/s15010-025-02698-3

Vancouver

Abaft S, Yassin Z, Ahmadinia M, Eshraghi A, Niari BG, Minaeian S, et al. Efficacy and safety of colistin–doxycycline combination therapy in multi-drug resistance Gram-negative infections: a double-blind randomized controlled trial. Infection. 2026. doi:10.1007/s15010-025-02698-3

BibTeX
@article{Abaft2026,
  author = {Abaft, Shaghayegh and Yassin, Zeynab and Ahmadinia, Mahdi and Eshraghi, Azadeh and Niari, Behnaz Gholizadeh and Minaeian, Sara and Farasatinasab, Maryam},
  title = {Efficacy and safety of colistin–doxycycline combination therapy in multi-drug resistance Gram-negative infections: a double-blind randomized controlled trial},
  journal = {Infection},
  year = {2026},
  doi = {10.1007/s15010-025-02698-3}
}
Kostenlos starten →